Details

Autor(en) / Beteiligte

• Halasa, Natasha B
• Olson, Samantha M
• Staat, Mary A
• Newhams, Margaret M
• Price, Ashley M
• Boom, Julie A
• Sahni, Leila C
• Cameron, Melissa A
• Pannaraj, Pia S
• Bline, Katherine E
• Bhumbra, Samina S
• Bradford, Tamara T
• Chiotos, Kathleen
• Coates, Bria M
• Cullimore, Melissa L
• Cvijanovich, Natalie Z
• Flori, Heidi R
• Gertz, Shira J
• Heidemann, Sabrina M
• Hobbs, Charlotte V
• Hume, Janet R
• Irby, Katherine
• Kamidani, Satoshi
• Kong, Michele
• Levy, Emily R
• Mack, Elizabeth H
• Maddux, Aline B
• Michelson, Kelly N
• Nofziger, Ryan A
• Schuster, Jennifer E
• Schwartz, Stephanie P
• Smallcomb, Laura
• Tarquinio, Keiko M
• Walker, Tracie C
• Zinter, Matt S
• Gilboa, Suzanne M
• Polen, Kara N
• Campbell, Angela P
• Randolph, Adrienne G
• Patel, Manish M

Titel

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2022-02, Vol.71 (7), p.264-270

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future, to protect them from COVID-19. Infants are at risk for life-threatening complications from COVID-19, including acute respiratory failure (1). Evidence from other vaccine-preventable diseases suggests that maternal immunization can provide protection to infants, especially during the high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent studies of COVID-19 vaccination during pregnancy suggest the possibility of transplacental transfer of SARS-CoV-2-specific antibodies that might provide protection to infants (3-5); however, no epidemiologic evidence currently exists for the protective benefits of maternal immunization during pregnancy against COVID-19 in infants. The Overcoming COVID-19 network conducted a test-negative, case-control study at 20 pediatric hospitals in 17 states during July 1, 2021-January 17, 2022, to assess effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants. Among 379 hospitalized infants aged <6 months (176 with COVID-19 [case-infants] and 203 without COVID-19 [control-infants]), the median age was 2 months, 21% had at least one underlying medical condition, and 22% of case- and control-infants were born premature (<37 weeks gestation). Effectiveness of maternal vaccination during pregnancy against COVID-19 hospitalization in infants aged <6 months was 61% (95% CI = 31%-78%). Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months.